A Physical Activity and Sitting Time Balance Index and All-Cause Mortality Risk

Sitting Time Balance Index

ESPRIT Trial

ESPRIT Trial

Industry Payments to Cardiologists

Industry Payments

37th ESC 2024 Congress Coverage: OCCUPI Trial

37th ESC 2024: OCCUPI Trial

36th ESC 2024 Congress Coverage: SWEDEGRAFT Trial

36th ESC 2024: SWEDEGRAFT Trial

35th ESC 2024 Congress Coverage: RIGHT Trial

35th ESC 2024: RIGHT Trial

34th ESC 2024 Congress Coverage: De-escalation to ticagrelor monotherapy vs. 12 months of dual antiplatelet therapy

34th ESC 2024: Ticagrelor monotherapy vs. dual antiplatelet therapy

33rd ESC 2024 Congress Coverage: MATTERHORN Trial

32nd ESC 2024: MATTERHORN Trial

32nd ESC 2024 Congress Coverage: Three Biomarkers and 30-Year Cardiovascular Outcomes in Women

32nd ESC 2024: Cardiovascular Outcomes in Women

31st ESC 2024 Congress Coverage: ESC 2024 Chronic Coronary Syndromes Guideline (3)

31st ESC 2024: ESC 2024 CCS Guideline (3)

30th ESC 2024 Congress Coverage: ESC 2024 Chronic Coronary Syndromes Guideline (2)

30th ESC 2024: ESC 2024 CCS Guideline (2)

29th ESC 2024 Congress Coverage: Noise and Air Pollution as Risk Factors for Hypertension

29th ESC 2024: Noise and Air Pollution as RF for HTN

28th ESC 2024 Congress Coverage: ESC 2024 Chronic Coronary Syndromes Guideline (1)

28th ESC 2024: ESC 2024 CCS Guideline (1)

27th ESC 2024 Congress Coverage: Women in Cardiology, RISE Conference

27th ESC 2024: RISE Conference

26th ESC 2024 Congress Coverage: Lowering of non–high-density lipoprotein cholesterol after Myocardial Infarction

26th ESC 2024: ILowering of non-HDL cholesterol after MI and prognosis

25th ESC 2024 Congress Coverage: ESC 2024 Guideline for Management of Peripheral Arterial and Aortic Diseases

25th ESC 2024: ESC 2024 PAAD Guideline

24th ESC 2024 Congress Coverage: EPIC-CAD Trial

24th ESC 2024: EPIC-CAD Trial

23rd ESC 2024 Congress Coverage: QUADRO Trial

23rd ESC 2024: QUADRO Trial

22nd ESC 2024 Congress Coverage: NOTION-3 Trial

22nd ESC 2024: NOTION-3 Trial

21st ESC 2024 Congress Coverage: PALISADE Trial

21st ESC 2024: PALISADE Trial

20th ESC 2024 Congress Coverage: OCEANIC-AF Trial

20th ESC 2024: OCEANIC-AF Trial

19th ESC 2024 Congress Coverage: Stop-or-Not Trial

19th ESC 2024: Stop-or-Not Trial

18th ESC 2024 Congress Coverage: ESC 2024

Hypertension Guideline

17th ESC 2024 Congress Coverage: Sudden Cardiac Death

Among Persons with Diabetes Aged 1–49 years

16th ESC 2024 Congress Coverage: ASSURE DES Trial

16th ESC 2024: ASSURE DES Trial

15th ESC 2024 Congress Coverage: PROTEUS Trial

15th ESC 2024: PROTEUS Trial

14th ESC 2024 Congress Coverage: SHAM-PVI Trial

14th ESC 2024: SHAM-PVI Trial

13th ESC 2024 Congress Coverage: SCOFF Trial

13th ESC 2024: SCOFF Trial

12th ESC 2024 Congress Coverage: GMRx2 Trials

12th ESC 2024: GMRx2 Trials

11th ESC 2024 Congress Coverage: RESHAPE-HF2

11th ESC 2024: RESHAPE-HF2

10th ESC 2024 Congress Coverage: EARTH-STEMI meta-analysis

10th ESC 2024: EARTH-STEMI meta-analysis

9th ESC 2024 Congress Coverage: BedMed and BedMed-Frail Trials

9th ESC 2024: BedMed and BedMed-Frail Trials

8th ESC 2024 Congress Coverage: Optical Coherence Tomography (OCT) Parameter Tracks Atherosclerosis Progression

8th ESC 2024: OCT Parameter Tracks Atherosclerosis Progression

7th ESC 2024 Congress Coverage: FLOW Trial

7th ESC 2024: FLOW Trial

6th ESC 2024 Congress Coverage: Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

6th ESC 2024: Vutrisiran

5th ESC 2024 Congress Coverage: MIRACLE-AF Trial

5th ESC 2024: MIRACLE-AF Trial

4th ESC 2024 Congress Coverage: PAUSE TAVI Trial

4th ESC 2024: PAUSE TAVI Trial

3rd ESC 2024 Congress Coverage: ABYSS Trial

2nd ESC 2024 Congress Coverage: FINEARTS-HF Trial

2nd ESC 2024: FINEARTS-HF Trial

1st ESC 2024 Congress Coverage: TIGHT K Trial

1st ESC 2024: TIGHT K Trial

Transcatheter Aortic Valve Impalanation Fails

Noninferiority to Surgery in Younger Patients

HRS24 Congress Coverage: Left Atrial Appendage Occlusion: New Evidence and Techniques

HRS24: LAA Occlusion

HRS24 Congress Coverage: Pulsed Field Ablation (PFA): a new Technique for the Treatment of Arrhythmia

HRS24: Pulsed Field Ablation (PFA)

HRS24 Congress Coverage: Anticoagulation in patients with device-detected AF, Artesia vs NOAH AFnet 6

HRS24: Artesia vs. NOAH AFnet 6

HRS24 Congress Coverage: Cardioneural Ablation for Treating Vasovagal Syncope

HRS24: CNA for Vasovagal Syncope

ACC.24 Congress Coverage: Remote Acute Assessment of Cardiac Patients Post-Acute Coronary Syndrome

ACC.24: TELE-ACS Trial

ACC.24 Congress Coverage: Superiority Trial of Enalapril to Prevent Anthracycline-induced Cardiotoxicity

ACC.24: PROACT Trial

ACC.24 Congress Coverage: Transcatheter or Surgical Treatment of Aortic-Valve Stenosis

ACC.24: DEDICATE-DZHK6 Trial

ACC.24 Congress Coverage: Self-Expanding vs. Balloon-Expandable Valve For TAVR in Patients With Small Valve Annulus

ACC.24: SMART Trial

ACC.24 Congress Coverage: Empagliflozin after Acute Myocardial Infarction

ACC.24: EMPACT-AMI trial

ACC.24 Congress Coverage: Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care

ACC.24: KARDIA-2 trial

ACC.24 Congress Coverage: Safety and Efficacy of Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy

ACC.24: IMPROVE-HCM trial

ACC.24 Congress Coverage: Interatrial shunt therapy in advanced heart failure

ACC.24: RELIEVE-HF trial

ACC.24 Congress Coverage: Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

ACC.24: REDUCE-IT trial

ACC.24 Congress Coverage: An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

ACC.24: VICTORION-INITIATE trial

ACC.24 Congress Coverage: Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events

ACC.24: BE ACTIVE Trial

ACC.24 Congress Coverage: A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication

ACC.24: TACTiC Trial

ACC.24 Congress Coverage: Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction

Infarction ACC.24: AEGIS-II Trial

ACC.24 Congress Coverage: Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy

ACC.24: ARISE-HF Trial

ACC.24 Congress Coverage: Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease

ACC.24: SGLT2i in ACHD

ACC.24 Congress Coverage: Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

ACC.24: Bridge TIMI 73a Trial

ACC.24 Congress Coverage: The Trial to Assess Chelation Therapy 2

ACC.24: TACT 2 Trial

ACC.24 Congress Coverage: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

ACC.24: Semaglutide in HFpEF and DM

ACC.24 Congress Coverage: Microaxial Flow Pump vs Standard Care for Infarct-Related Cardiogenic Shock

ACC.24: DanGer Shock Trial

ACC.24 Congress Coverage: REDUCE-AMI Trial

ACC.24: REDUCE-AMI

ACC.24 Congress Coverage: Mandibular Advancement Device vs CPAP in Obstructive Sleep Apnea

ACC.24: MAD vs CPAP in OSA

ACC.24 Congress Coverage: ORBITA-COSMIC Trial

ACC.24: ORBITA-COSMIC

ACC.24 Congress Coverage: ULTIMATE-DAPT Trial

ACC.24: ULTIMATE-DAPT

Impact: Evaluation of a Best-Practice Advisory for Primary Aldosteronism Screening

Impact: EHR tool for aldosteronism diagnosis

Impact: Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors

Impact: Nitrates and PDE-5 inhibitors and Nitrates in CAD

Impact: Why Do GLP-1 Drugs Stop Working, and What to Do About It?

Impact: GLP-1 agonists in the treatment of obesity

mpact: Cardiovascular and Non-cardiovascular Prescribing and Mortality After Takotsubo – Comparison With Myocardial Infarction and General Population

Impact: Mortality After Takotsubo – Comparison With MI and General Population

Impact: Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism

mpact: High Risk PE

Impact: Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention

Impact: SAPT 1 year after PCI

Impact: Validity of a speech analysis app for the prediction of HF worsening

Impact: Speech analysis to predict HF events, Cordio HearO

AHA23 Congress Coverage: A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina: The ORBITA-2 trial

A23 Congress Coverage: PCI for Stable Angina (ORBITA-2 Trial)

AHA23 Congress Coverage: Impact of Female Sex on Cardiogenic Shock Outcomes: A Cardiogenic Shock Working Group Report

A23 Congress Coverage: Cardiogenic Shock in Women

AHA23 Congress Coverage: Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

A23 Congress Coverage: Lepodisiran Dose-Ascending Trial

AHA23 Congress Coverage: Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT trial

HA23 Congress Coverage: BP control after hypertensive pregnancy (POP-HT)

AHA23 Congress Coverage: Daily Marijuana Use is Associated With Incident Heart Failure: “All of Us” Research Program

AHA23 Congress Coverage: Daily Marijuana and HF ("All of Us Research Program")

AHA23 Congress Coverage: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation: ARTESIA trial

AHA23 Congress Coverage: Apixaban in subclinical AF (ARTESIA)

AHA23 Congress Coverage: Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure: DAPA-MI trial

AHA23 Congress Coverage: Dapagliflozin in MI without DM or HF (DAPA MI)

AHA23 Congress Coverage: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes: SELECT trial

AHA23 Congress Coverage: Semaglutide in obesity and no DM (SELECT trial)

AHA23 Congress Coverage: Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia: MINT trial

AHA23 Congress Coverage: Blood Transfusion in MI and Anemia (MINT trial)

AHA23 Congress Coverage: Hypertension Treatment and Risk of Dementia

AHA23 Congress Coverage: HTN and Dementia

Impact: When Does a Calcium Score Equate to Secondary Prevention?

Impact: New Evidence for Interpreting Calcium Score

ESC 2023 Congress Coverage: PUSH-AHF

ESC 2023: PUSH-AHF

ESC 2023 Congress Coverage: RIGHT

ESC 2023: RIGHT

ESC 2023 Congress Coverage: RED-CVD

ESC 2023: RED-CVD

ESC 2023 Congress Coverage: NITRATE-CIN

ESC 2023: NITRATE-CIN

ESC 2023 Congress Coverage: DICTATE-AHF

ESC 2023: DICTATE-AHF

ESC 2023 Congress Coverage: ARREST

ESC 2023: ARREST

ESC 2023 Congress Coverage: ONCO-DVT

ESC 2023: ONCO-DVT

ESC 2023 Congress Coverage: ARAMIS

ESC 2023: ARAMIS

ESC 2023 Congress Coverage: OPT-BIRISK

ESC 2023: OPT-BIRISK

ESC 2023 Congress Coverage: CASTLE-HTx

ESC 2023: CASTLE-HTx

ESC 2023 Congress Coverage: MULTISTARS AMI

ESC 2023: MULTISTARS AMI

ESC 2023 Congress Coverage: ADVENT

ESC 2023: ADVENT

ESC 2023 Congress Coverage: ATTRibute CM

ESC 2023: ATTRibute

ESC 2023 Congress Coverage: STOP-DAPT 3

ESC 2023: STOP-DAPT 3

ESC 2023 Congress Coverage: FIRE

ESC 2023: FIRE

ESC 2023 Congress Coverage: BUDAPEST-CRT Upgrade

ESC 2023: BUDAPEST-CRT Upgrade

ESC 2023 Congress Coverage: HEART-FID

ESC 2023: HEART-FID

ESC 2023 Congress Coverage: QUEST

ESC 2023: QUEST

ESC 2023 Congress Coverage: NOAH-AFNET 6

ESC 2023: NOAH-AFNET 6

ESC 2023 Congress Coverage: COP-AF

ESC 2023: COP-AF

ESC 2023 Congress Coverage: STEP-HFpEF

ESC 2023: STEP-HFpEF

Overview of ESC 2023 Congress

What to expect from ESC 2023

Impact: Clinical Outcomes of Calcium Channel Blockers versus Beta Blockers after Acute MI

Impact: CCBs VS BBs post AMI

Impact: Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Impact: Zilebesiran

Impact: Early versus Later Anticoagulation for Stroke with Atrial Fibrillation

Impact: Anticoagulation in AF and stroke

Impact: Combination lipid-lowering therapy after PCI

Impact: Dyslipidemia treatment after PCI

PROMIS-II trial explained

Arterialization of deep veins in CLTI

Impact: Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure

Impact: Sacubitril/Valsartan and renal function in HF

CardioWatch, Season 2 Episode 6

CardioWatch S02E06

Impact: Healthy Eating Patterns and Risk of Total and Cause-Specific Mortality

Impact: Healthy Eating and mortality risk

Impact: Survival difference in dyspnea and chest pain as an initial symptom of NSTEMI

Impact: Dyspnea vs. Chest Pain in the survival of NSTEMI patients

Impact: Management of ACS in older adults, an AHA statement

Impact: ACS in the elderly

Impact: single chest x-ray could predict 10-year CVD risk

Impact: one CXR to determine 10-yr CVD risk

CardioWatch, Season 2 Episode 5

CardioWatch S02E05

PANTHER: Clopidogrel overcoming the old rival

A quick review on PANTHER study

Impact: The association between dairy intake and risk of cardiovascular disease and mortality in patients with stable angina pectoris

Impact: Dairy consumption and cardiovascular risk

Impact: Experts Express Caution Over Type 2 Diabetes-Tea Drinking Claim

Impact: Tea consumption and DM risk

Impact: The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality

Impact: Coffee consumption and CV risk

Impact: Dual antiplatelet therapy with Ticagrelor and graft failure after coronary artery bypass grafting

Dual antiplatelet Tx. with Ticagrelor and graft failure after CABG

Impact: RADIANCE II: Pivotal study, renal denervation for stage II Hypertension

Impact: RADIANCE II, pivotal study

Impact: Acetaminophen in comparison to NSAIDs in cardiovascular diseases

Impact: Acetaminophen vs. NSAIDs in CVD

Impact: Improved Likelihood of Survival With the Use of the Head-Up CPR Bundle for Non-Shockable Cardiac Arrest

Impact: Improved Survival With the Head-Up CPR Bundle for Non-Shockable Cardiac Arrest

Impact: Pulmonary Artery Denervation for Pulmonary Arterial Hypertension

Impact: Pulmonary Artery Denervation for PAH

Impact: Association of Sacubitril/Valsartan administration and the severity of functional MR in HFrEF

Impact: Sacubitril/Valsartan and MR severity in HFrEF

Impact: Effect of statin therapy on muscle symptoms

Impact: Effect of statin therapy on muscle symptoms

CardioWatch, Season 2 Episode 4

CardioWatch S02E04

CardioWatch, Season 2 Episode 3

CardioWatch S02E03

CardioWatch, Season 2 Episode 2

CardioWatch S02E02

American College of Cardiology (ACC) congress 2022 landmark trials review

ACC 2022 congress coverage

At a glance: Ticagrelor and prevention of recurrent thrombotic events in CCS

Ticagrelor and secondary prevention in CCS

TicaHub 2: Ticagrelor in clinical trials

TicaHub 2

CardioWatch, Season 2 Episode 1

CardioWatch S02E01

Rivaroxaban vs Apixaban in major ischemic or hemorrhagic events in AF

Rivaroxaban vs Apixaban in AF

Antiplatelet journal scan

A review on recent antiplatelet therapy trials

Landmark trials of ESC 2021 congress

2021 post-ESC headlines

Cardio-Watch Podcast: Episode 7, ESC 2021 special

The seventh episode of Cardio-Watch: ESC 2021

Therapeutic anticoagulation with Heparin in critically and non-critically ill patients with COVID-19

The role of Heparin in the management of thrombosis in COVID-19

Cardio-Watch Podcast: Episode 6, Electrophysiology

The sixth episode of Cardio-Watch: Electrophysiology

Effect of Neprilysin Inhibition on LV Remodeling in Asymptomatic LV Systolic Dysfunction After MI

Neprilysin Inhibitors to prevent LV remodeling post MI

Midodrine for the prevention of vasovagal syndrome: a randomized clinical trial

Midodrine in vasovagal syndrome prevention

Long-term event-free and overall survival with Dapagliflozin in HFrEF patients

Impact of Dapagliflozin on the survival of HFrEF patients

Milrinone compared with Dobutamine in cardiogenic shock: DOREMI trial

Milrinone vs. Dobutamine: DOREMI trial

Cardio-Watch Podcast: Episode 5, cardiometabolic disorders

The fifth episode of Cardio-Watch: cardiometabolic disorders

Safety and Efficacy of different antithrombotic strategies after TAVI

Post-TAVI antithrombotic strategies

Testing for Iron deficiency and use of Ferric Carboxymaltose in HF patients

Diagnosis and management of Iron deficiency in HF patients

Cardio-Watch Podcast: Episode 4, Dyslipidemia

The fourth episode of Cardio-Watch: Dyslipidemia

Cardio-Watch podcast: Episode 3, Atrial fibrillation and Flutter

The Third episode of Cardio-Watch: AF

Left Atrial Appendage Occlusion to prevent Stroke

Preventing Stroke by surgical LA Appendage Occlusion

A review on four landmark anti-platelet therapy trials

The latest updates on anti-platelet therapy from 4 important trials

Cardio-Watch podcast: Episode 2, Hypertension

The second episode of Cardio-Watch: Hypertension

Aspirin vs Clopidogrel for chronic maintenance monotherapy after PCI

The comparison of Clopidogrel and Aspirin monotherapy after PCI (HOST-EXAM trial)

Impact: DAPT vs. Aspirin in patients with stroke or TIA

A recent meta-analysis about antiplatelet therapy in stroke

Cardio-Watch Podcast: Episode one; COVID-19 and the heart

The first episode of Cardio-Watch podcast

Impact: the paradox of physical activity in cardiovascular disease

The contemporary Copenhagen general population study

Impact: No-LVT trial

Comparative study of oral anticoagulation in left ventricular thrombi

Impact: Statin treatment and muscle symptoms

StatinWise Trial

Impact: Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomized, open-label trial

Continue vs Stop of RAS inhibitors in patients with COVID-19

Impact: EMPA-RESPONSE-AHF

Empagliflozin effects on clinical outcomes in patients with ADHF (EMPA-RESPONSE-AHF)

A Polypill For the Prevention of CVD in Intermediate Risk Patients: Results of the International Polycap Study (TIPS-3 Trial)

A quick review on the findings of TIPS-3 trial from AHA congress 2020

The role of Omega 3 and Vitamin D in the Primary Prevention of AF (VITAL-RHYTHM Trial)

Dietary Supplements and AF

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with T2DM and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

The Important findings of SCORED trial from AHA 2020 congress in brief

High Dose Vs Standard Dose Influenza Vaccine in Patients with a High-Risk for Cardiovascular Disease (INVESTED)

A quick review on the findings of INVESTED trial from AHA congress 2020

Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in HF (GALACTIC-HF Trial)

A quick review on the findings of GALACTIC-HF trial from AHA congress 2020

Early Coronary CT Angiography in Patients with Suspected or Provisionally Diagnosed ACS (RAPID CTCA trial)

Early Coronary CT-angiography in ACS

Rilonacept (IL-1α and β inhibitor) in the treatment of recurrent pericarditis

a pivotal symptomatology and outcomes study (RHAPSODY Trial)

Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor+ASA for Prevention of Stroke and Death (THALES Trial)

The effects of Ticarelor+ASA in Acute Stroke

Effects of Evolocumab on Complex Coronary Disease Requiring Revascularization

Evolocumab in the pipeline

Sotagliflozin and Cardiovascular Events in T2DM Post Worsening HF (SOLOIST-WHF)

Sotagliflozin in T2DM and exacerbated HF

Ticagrelor VS. Clopidogrel in elective PCI

The findings of ALPHEUS trial

Ferric Carboxymaltose for iron deficiency at discharge after acute heart failure (AFFIRM-AHF)

Iron supplementation in acute heart failure

Rivaroxaban in Patients with AF and a Bioprosthetic Mitral Valve

The findings of RIVER trial

Cryoablation or Drug Therapy for the Initial Treatment of AF (EARLY-AF)

Treatment strategies of AF

Enhanced Monitoring for AF Following Cardiac Surgery (SEARCH-AF)

Detection of AF after cardiac surgery

Finerenone Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD Trial)

Finerenone protecting kidneys

Daily Cardiology Journal Club: 4th Session – EAST-AFNET4 Trial

Monthly Case-Based Clinical Problem Solving

Daily Cardiology Journal Club: 3rd Session – EMPEROR-REDUCED Trial

Monthly Case-Based Clinical Problem Solving

Impact: Icosapent ethyl in elevated TG

The findings of EVAPORATE trial

Impact: Efficacy and safety of Trimetazidine after PCI

The findings of ATPCI trial

Impact: adding Ticagrelor to Aspirin in CABG patients

The findings of POPular CABG trial

Impact: Colchicine in patients with acute coronary syndrome

The findings of COPS trial

Impact: Colchicine in patients with chronic coronary syndrome

The findings of LoDoCo2 trial

Impact: Mavacamten for the treatment of symptomatic HCM

The findings of EXPLORER HCM trial

Impact: Aspirin with or without Clopidogrel after TAVI

The findings of POPULAR TAVI trial

Impact: cardiovascular and renal outcomes of Empagliflozin in HF

The findings of EMPEROR-REDUCED trial

Impact: Early rhythm control in AF

The findings of EAST-AFNET 4 trial

Impact: Intracoronary infusion of bone marrow-derived mononuclear cells in AMI

The findings of BAMI trial

Impact: Time-to-treatment of Colchicine and post-MI cardiovascular outcomes

The findings of COLCOT trial

Daily Cardiology Journal Club: Second Session – ISCHEMIA Trial

Monthly Case-Based Clinical Problem Solving

Daily Cardiology Journal Club: First Session – How to setup an effective Journal Club?

Monthly Case-Based Clinical Problem Solving

Benefits of Targeting for a <70 mg/dL LDL Cholesterol During 5 Years After Ischemic Stroke

The findings of TST study

Electrical versus pharmacological cardioversion for acute AF in emergency settings

The findings of RAFF2 trial

Predicting the Risk of Post-stroke Atrial Cardiopathy

An interim analysis from ACARDIA trial

Dapagliflozin in concurrent Atrial Fibrillation and T2DM

Insights from DECLARE-TIMI 58 Trial

Intensive LDL lowering beyond current recommendations for MACE prevention

A meta-analysis of RCTs

OACs vs. antiplatelet or placebo for stroke prevention in patients with HF and sinus rhythm

A meta-analysis of RCTs

Association of Anticoagulation Therapy with the Risk of Fracture in AF Patients

The findings of a recent study

Complete vs. Culprit-only Revascularization in Patients with STEMI and Multi-Vessel Coronary Disease

A meta-analysis of RCTs

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in T2DM

The renal and cardiovascular protective effects of SGLT2 inhibitors

Intensive Blood Pressure lowering and the Concerns about Falling

The findings of SPRINT trial

Timing of Staged Non-Culprit Artery PCI in STEMI

The findings of COMPLETE Trial about PCI timing

Inclisiran for patients with ASCVD and elevated LDL

The findings of ORION-10 trial in ASCVD patients

Dapagliflozin in non-DM Patients with HF and Reduced EF

The findings of DAPA-HF trial in non-diabetics

Inclisiran in Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated LDL

The findings of ORION-9 trial about Inclisiran in HeFH

The Efficacy and Safety of Low-Dose Colchicine after MI

The findings of COLCOT trial about colchicine post-MI

Optimal Medical Therapy vs. Revascularization in Chronic Coronary Syndrome

The findings of ISCHEMIA trial

Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis

The findings of RECOVERY trial

AF after Non-Cardiac Surgery Increases the Risk of Stroke

A meta-analysis of post-operative AF studies

Rivaroxaban vs. Vit K Antagonist in Antiphospholipid Syndrome

Rivaroxaban versus warfarin in APS

Antithrombotic treatment after CABG

A recent meta-analysis on post-CABG Antithrombotic therapy

Triglyceride Lowering and Cardiovascular Risk Reduction

A Systematic Review and Meta-Analysis of RCTs on TG lowering drugs

Risk of Mortality Following Catheter Ablation of AF

Mortality risk after AF ablation

Bedtime hypertension treatment improves cardiovascular risk reduction

The findings of Hygia Chronotherapy Trial

Peri-operative beta-blockers in non-cardiac surgery

The findings of Cochrane database systematic review

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease

The findings of EXCEL Trial

Ticagrelor with or without Aspirin in High-Risk patients after PCI

The findings of TWILIGHT Trial

Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy

The findings of STICH trial

Pantoprazole in Patients Receiving Rivaroxaban and/or Aspirin

The findings of COMPASS trial

OAC Monotherapy in Patients with Stable CAD and Non-valvular AF

OACs in Stable CAD and AF

Acute vs Subacute Coronary Angiography in NSTEMI

The findings of NONSTEMI Trial

Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI

P2Y12 loading dose timing in PCI

Lisinopril vs Carvedilol for Trastuzumab Cardiotoxicity in Breast Cancer

Preventing the cardiotoxicity of Trastuzumab

Ezetimibe for the prevention of heart disease and death

The role of Ezetimibe in reducing CVD adverse outcomes

Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half

The findings of REASTART Trial

Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or TIA

DAPT after ischemic stroke or TIA

Canagliflozin and Renal Outcomes in T2Dm and Nephropathy

The findings of CREDENCE Trial

Anticoagulation in HF and sinus rhythm

OACs in HF and sinus rhythm

TAVR vs SAVR: insights from ACC.19

The findings of PARTNER 3 and EVOLUT trials

Antithrombotic Therapy after ACS or PCI in AF

The findings of AUGUSTUS Trial

Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis

Stenting vs endarterectomy in symptomatic carotid stenosis